New Zealand markets closed

Aelis Farma SA (AELIS.PA)

Paris - Paris Delayed price. Currency in EUR
Add to watchlist
14.140.00 (0.00%)
As of 10:27AM CET. Market open.

Aelis Farma SA

146 rue Léo Saignat
Neurocentre Magendie
Bordeaux 33077
33 5 57 57 37 70

Full-time employees22

Key executives

NameTitlePayExercisedYear born
Dr. Pier Vincenzo Piazza M.D., Ph.D.CEO & Director501.14kN/A1961
Ms. Marie Line LefevreHead of Fin.N/AN/AN/A
Stephanie MonlezunChief Operating OfficerN/AN/AN/A
Ms. Lea FloquetHead of LegalN/AN/AN/A
Ms. Sandy FabreHead of Discovery & IP LeaderN/AN/AN/A
Ms. Aurelie BoucardHead of Preclinical Devel.N/AN/AN/A
Ms. Helle MengelHead of Clinical Devel.N/AN/AN/A
Ms. Corinne ChaimbaultHead of Pharmaceutical Devel.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.

Corporate governance

Aelis Farma SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.